Stockreport
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024 [Yahoo! Finance]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
– Updated Results from Phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus A nti-PD-1 Zimberelimab, to be Presented – – Pilot Study Results of Yescarta ® in Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas, an Area of Unmet Clinical Need, to be Presented Orally – FOSTER CITY, Calif. & SANTA MONICA, Calif., May 07, 2024 BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia and lymphoma. New Data Provide Detail on Trodelvy in Non-Small Cell Lung Cancer (NSCLC) Gilead is presenting primary results from the global Phase 3 EVOKE-01 study of Trodelvy ® (sacituzumab govitecan-hziy) versus docet
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy[Business Wire]
- ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder [Yahoo! Finance][Yahoo! Finance]
- One stock is dragging down the S&P 500's earnings growth [Yahoo! Finance Canada][Yahoo! Finance Canada]
- One stock is dragging down the S&P 500's earnings growth [Yahoo! Finance][Yahoo! Finance]
- Leap Therapeutics Reports First Quarter 2024 Financial Results [Yahoo! Finance][Yahoo! Finance]
- More
GILD
SEC Filings
SEC Filings
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- GILD's page on the SEC website
- More